Tumor cells exploit many signaling pathways to avoid detection by the host immune system, thereby limiting the potential of cancer immunotherapies. iTeos Therapeutics S.A. is developing small molecule immunomodulators that block these escape pathways, which could potentially boost and prolong the effects of cancer vaccines.

iTeos spun out of the Ludwig Institute for Cancer Research Ltd. (LICR) and the de Duve Institute at the Université catholique de Louvain last August to translate the LICR's scientific assets into immunomodulatory cancer therapies.